Anchor Capital Advisors Lowers stake in Haemonetics Corporation (HAE)

Haemonetics Corporation (HAE) : Anchor Capital Advisors reduced its stake in Haemonetics Corporation by 0.63% during the most recent quarter end. The investment management company now holds a total of 905,466 shares of Haemonetics Corporation which is valued at $31,021,265 after selling 5,768 shares in Haemonetics Corporation , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Haemonetics Corporation makes up approximately 0.80% of Anchor Capital Advisors’s portfolio.

Other Hedge Funds, Including , Cardinal Capital Management boosted its stake in HAE in the latest quarter, The investment management firm added 659 additional shares and now holds a total of 8,906 shares of Haemonetics Corporation which is valued at $270,030. Haemonetics Corporation makes up approx 0.11% of Cardinal Capital Management’s portfolio.

Haemonetics Corporation opened for trading at $34.24 and hit $35.03 on the upside on Thursday, eventually ending the session at $34.82, with a gain of 1.63% or 0.56 points. The heightened volatility saw the trading volume jump to 6,24,342 shares. Company has a market cap of $1,777 M.

On the company’s financial health, Haemonetics Corporation reported $0.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 1, 2016. Analyst had a consensus of $0.29. The company had revenue of $210.00 million for the quarter, compared to analysts expectations of $205.41 million. The company’s revenue was down -1.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.35 EPS.

Many Wall Street Analysts have commented on Haemonetics Corporation. Company shares were Reiterated by Jefferies on Aug 2, 2016 to “Buy”, Firm has raised the Price Target to $ 40 from a previous price target of $32 .Company shares were Reiterated by The Benchmark Company on Aug 2, 2016 to “Hold”, Firm has raised the Price Target to $ 32 from a previous price target of $28 .Haemonetics Corporation was Upgraded by Goldman to ” Neutral” on May 16, 2016.

Haemonetics Corporation is a healthcare company which provides blood management solutions to its customers. The Company’s portfolio of integrated devices information management and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma Blood Center Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma North America Blood Center and Hospital Europe Asia Pacific and Japan.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Haemonetics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Haemonetics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.